WO2016040767A3 - Chrdl-1 epitopes and antibodies - Google Patents
Chrdl-1 epitopes and antibodies Download PDFInfo
- Publication number
- WO2016040767A3 WO2016040767A3 PCT/US2015/049622 US2015049622W WO2016040767A3 WO 2016040767 A3 WO2016040767 A3 WO 2016040767A3 US 2015049622 W US2015049622 W US 2015049622W WO 2016040767 A3 WO2016040767 A3 WO 2016040767A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- chrdl
- fragments
- derivatives
- antibodies
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
The present invention provides compositions and methods relating to or derived from antigen binding proteins to CHRDL-1. Human, humanized, and chimeric antibodies, as well as fragments and derivatives thereof are further contemplated where such antibodies are defined as selectively binding to CHRDL-1 in particular regions of the protein that result in neutralization and thereby treatment of disorders associated with CHRDL-1 expression. Other embodiments include nucleic acids encoding such antigen binding proteins, and fragments and derivatives thereof, as well as polypeptides, cells, methods of making and using antigen binding proteins, fragments and derivatives thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462049975P | 2014-09-12 | 2014-09-12 | |
US62/049,975 | 2014-09-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2016040767A2 WO2016040767A2 (en) | 2016-03-17 |
WO2016040767A3 true WO2016040767A3 (en) | 2016-04-28 |
Family
ID=54150742
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2015/049622 WO2016040767A2 (en) | 2014-09-12 | 2015-09-11 | Chrdl-1 epitopes and antibodies |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2016040767A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3167936A1 (en) * | 2020-01-16 | 2021-07-22 | Cohava Gelber | Humanized antibodies specific for myeloma and ovarian cancer cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014159764A1 (en) * | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
DE3374837D1 (en) | 1982-02-17 | 1988-01-21 | Ciba Geigy Ag | Lipids in the aqueous phase |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
EP0143949B1 (en) | 1983-11-01 | 1988-10-12 | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION | Pharmaceutical composition containing urokinase |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
US4935233A (en) | 1985-12-02 | 1990-06-19 | G. D. Searle And Company | Covalently linked polypeptide cell modulators |
JPS63502716A (en) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | How to enhance glycoprotein stability |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
US5011912A (en) | 1986-12-19 | 1991-04-30 | Immunex Corporation | Hybridoma and monoclonal antibody for use in an immunoaffinity purification system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5683888A (en) | 1989-07-22 | 1997-11-04 | University Of Wales College Of Medicine | Modified bioluminescent proteins and their use |
US5292658A (en) | 1989-12-29 | 1994-03-08 | University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center | Cloning and expressions of Renilla luciferase |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
DK0710719T3 (en) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Generation of xenogenic antibodies |
US6713610B1 (en) | 1990-01-12 | 2004-03-30 | Raju Kucherlapati | Human antibodies derived from immunized xenomice |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
GB9014932D0 (en) | 1990-07-05 | 1990-08-22 | Celltech Ltd | Recombinant dna product and method |
EP0814159B1 (en) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Transgenic mice capable of producing heterologous antibodies |
US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
CA2105984C (en) | 1991-03-11 | 2002-11-26 | Milton J. Cormier | Cloning and expression of renilla luciferase |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5262522A (en) | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
JPH05244982A (en) | 1991-12-06 | 1993-09-24 | Sumitomo Chem Co Ltd | Humanized b-b10 |
JPH07509137A (en) | 1992-07-24 | 1995-10-12 | セル ジェネシス,インク. | Production of xenoantibodies |
JP3589665B2 (en) | 1992-10-23 | 2004-11-17 | イミュネックス・コーポレーション | Preparation of soluble oligomeric proteins |
US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
DE69435112D1 (en) | 1993-09-10 | 2008-08-21 | Univ Columbia | USE OF GREEN FLUORESCENCE PROTEIN |
WO1995021191A1 (en) | 1994-02-04 | 1995-08-10 | William Ward | Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein |
US5777079A (en) | 1994-11-10 | 1998-07-07 | The Regents Of The University Of California | Modified green fluorescent proteins |
ATE390933T1 (en) | 1995-04-27 | 2008-04-15 | Amgen Fremont Inc | HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | Human antibodies derived from immunized xenomice |
US5874304A (en) | 1996-01-18 | 1999-02-23 | University Of Florida Research Foundation, Inc. | Humanized green fluorescent protein genes and methods |
US5804387A (en) | 1996-02-01 | 1998-09-08 | The Board Of Trustees Of The Leland Stanford Junior University | FACS-optimized mutants of the green fluorescent protein (GFP) |
US5876995A (en) | 1996-02-06 | 1999-03-02 | Bryan; Bruce | Bioluminescent novelty items |
US5925558A (en) | 1996-07-16 | 1999-07-20 | The Regents Of The University Of California | Assays for protein kinases using fluorescent protein substrates |
US5976796A (en) | 1996-10-04 | 1999-11-02 | Loma Linda University | Construction and expression of renilla luciferase and green fluorescent protein fusion genes |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
EP1015872B1 (en) | 1996-12-12 | 2005-03-02 | Prolume, Ltd. | Apparatus and method for detecting and identifying infectious agents |
CA2196496A1 (en) | 1997-01-31 | 1998-07-31 | Stephen William Watson Michnick | Protein fragment complementation assay for the detection of protein-protein interactions |
US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
JP2002507410A (en) | 1998-03-27 | 2002-03-12 | プロルーム・リミテッド | Luciferases, fluorescent proteins, nucleic acids encoding luciferases and fluorescent proteins and their use in diagnostics, high-throughput screening and novel items |
CA2341029A1 (en) | 1998-08-17 | 2000-02-24 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
US6833268B1 (en) | 1999-06-10 | 2004-12-21 | Abgenix, Inc. | Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions |
GB9928787D0 (en) | 1999-12-03 | 2000-02-02 | Medical Res Council | Direct screening method |
GB0025144D0 (en) | 2000-10-13 | 2000-11-29 | Medical Res Council | Concatenated nucleic acid sequences |
US20040202995A1 (en) | 2003-04-09 | 2004-10-14 | Domantis | Nucleic acids, proteins, and screening methods |
US9300829B2 (en) | 2014-04-04 | 2016-03-29 | Canon Kabushiki Kaisha | Image reading apparatus and correction method thereof |
-
2015
- 2015-09-11 WO PCT/US2015/049622 patent/WO2016040767A2/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014159764A1 (en) * | 2013-03-14 | 2014-10-02 | Amgen Inc. | Chrdl-1 antigen binding proteins and methods of treatment |
Non-Patent Citations (3)
Title |
---|
"Anti-CHRDL1 antibody ab57933 1", 1 January 2014 (2014-01-01), XP055232972, Retrieved from the Internet <URL:http://www.abcam.com/chrdl1-antibody-ab57933.html> [retrieved on 20151202] * |
B. W. LARMAN ET AL: "Chordin-like 1 and Twisted Gastrulation 1 Regulate BMP Signaling following Kidney Injury", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY., vol. 20, no. 5, 8 April 2009 (2009-04-08), US, pages 1020 - 1031, XP055232973, ISSN: 1046-6673, DOI: 10.1681/ASN.2008070768 * |
UEKI TAKATOSHI ET AL: "A novel secretory factor, Neurogenesin-1, provides neurogenic environmental cues for neural stem cells in the adult hippocampus", JOURNAL OF NEUROSCIENCE, THE SOCIETY, WASHINGTON, DC, US, vol. 23, no. 37, 17 December 2003 (2003-12-17), pages 11732 - 11740, XP009179269, ISSN: 1529-2401 * |
Also Published As
Publication number | Publication date |
---|---|
WO2016040767A2 (en) | 2016-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201891435A1 (en) | HUMANIZED MONOCLONAL ANTIBODIES, MONOCLONAL ANTIBODIES MOUSE OR CHEMERIC MONOCLONAL ANTIBODIES AGAINST CD47 | |
WO2017015560A3 (en) | Antibody therapeutics that bind lag3 | |
WO2016144803A3 (en) | Antibody therapeutics that bind tim3 | |
MX2022011935A (en) | Antibody therapeutics that bind ctla4. | |
MX2017014908A (en) | Trispecific binding proteins and methods of use. | |
WO2017075432A3 (en) | Anti-siglec-9 antibodies and methods of use thereof | |
EA201792221A1 (en) | ANTIBODIES AGAINST SORTILINE AND METHODS OF THEIR APPLICATION | |
WO2017193032A3 (en) | Bispecific binding proteins and uses thereof | |
WO2017062672A3 (en) | Anti-trem2 antibodies and methods of use thereof | |
WO2016141328A3 (en) | Antibody therapeutics that bind cd47 | |
WO2016065323A3 (en) | Single domain antibodies directed against intracellular antigens | |
WO2015112886A3 (en) | Binding proteins and methods of use thereof | |
PH12017500331A1 (en) | Antigen binding proteins that bind cxcr5 | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
WO2016164657A3 (en) | Antibody therapeutics that bind cd123 | |
WO2015161267A3 (en) | Humanized and chimeric monoclonal antibodies to cd99 | |
WO2016193872A3 (en) | Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor | |
WO2015184403A3 (en) | Anti-epidermal growth factor receptor (egfr) antibodies | |
WO2018069871A3 (en) | Anti-kras binding proteins | |
PH12017500332A1 (en) | Antigen binding proteins that bind cxcr3 | |
WO2016020882A3 (en) | Angiopoetin-like 4 (angptl4) antibodies and methods of use | |
MA39847A (en) | Antigen binding proteins that bind wisp1 | |
WO2016063026A3 (en) | Selective nav protein binders | |
WO2015117088A3 (en) | Antibody based reagents that specifically recognize neurodegenerative disease related forms of the protein tdp-43 | |
WO2017019957A3 (en) | Binding proteins and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15767043 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 15767043 Country of ref document: EP Kind code of ref document: A2 |